Log In
Print
BCIQ
Print
Print this Print this
 

UshStat

  Manage Alerts
Collapse Summary General Information
Company Oxford BioMedica plc
DescriptionLentiVector-based gene therapy expressing a gene encoding myosin VIIA (MYO7A; USH1B)
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Lentivirus
Latest Stage of DevelopmentPhase I/II
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat retinitis pigmentosa (RP) associated with Usher syndrome Type 1B
Regulatory Designation

EU - Orphan Drug (Treat retinitis pigmentosa (RP) associated with Usher syndrome Type 1B)

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today